SSY Group Issues Profit Warning as Pricing and Demand Pressures Hit 2025 Earnings

An update from SSY Group ( (HK:2005) ) is now available.

SSY Group has warned that profit attributable to equity shareholders for 2025 is expected to fall by 45% to 60% from HK$1.06 billion in 2024, driven by weaker turnover amid a normalized post-influenza demand environment in China. The company cited the absence of large-scale epidemics, tighter medical insurance cost controls, expanded volume-based procurement schemes and lost centralized procurement sales of Bromhexine Hydrochloride ampoule injections as key pressures, but stressed it maintains a solid financial position and is pushing product diversification and sales in oral and bulk pharmaceutical products to mitigate pricing and competitive headwinds.

Management emphasized that the figures are based on unaudited internal accounts and subject to change once the 2025 results are finalized and audited. The group plans to closely monitor market conditions through 2026 and take measures to improve performance, while urging shareholders and potential investors to exercise caution when dealing in its securities pending the formal annual results announcement and report.

The most recent analyst rating on (HK:2005) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

More about SSY Group

SSY Group Limited is a Hong Kong-listed pharmaceutical company incorporated in the Cayman Islands, focusing on intravenous infusion solutions and other medicines for the PRC market. The group has been diversifying its portfolio in recent years, increasing sales of oral preparations and bulk pharmaceutical products to optimize its product mix and strengthen its financial resilience.

YTD Price Performance: 7.07%

Average Trading Volume: 4,758,894

Technical Sentiment Signal: Sell

Current Market Cap: HK$8.94B

See more data about 2005 stock on TipRanks’ Stock Analysis page.